Joe Rabin, Editor

About the Author Joe Rabin, Editor

Joe is an intern at Smarter Analyst. He has written on a broad range of topics, including: financial trading, career development, cybersecurity, gamification, network access control, recreation and more.

Rosenblatt Sets Bullish Expectations on Oracle Corporation (ORCL) Ahead of F1Q18 Print

ORCL’s ability to show improving margins is key for short-term success, says analyst.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

Activision Blizzard, Inc. (ATVI) Destiny 2 Launch Could Provide Upside: Piper Jaffray

Top analyst takes note that Activision eyes Asian market with October PC release of newest video game.

Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.